



Recent Developments of Coagulation Factor Products in Hemophilia Treatment

Guest Editor:

Dr. Samantha Pasca

Department of Biomedical
Sciences (DSB), University
Hospital of Padua, 35138 Padua,
Italy

Deadline for manuscript
submissions:

closed (20 August 2023)

Message from the Guest Editor

In recent years, hemophilia therapy has made significant progress. Several new drugs have been added to the list of available treatments, significantly improving patients' quality of life. The extended half-life factor concentrates have enabled a reduced number of infusions, maintaining (and indeed, often increasing) the efficacy of treatments. These new drugs have also led to a reduction in bleeding, bringing us one step closer to the coveted “zero bleeds”, which is the ultimate goal of clinicians and patients. Another advantage of these concentrates is their versatility; thanks to the use of pharmacokinetics and an accurate anamnesis that considers the needs and wishes of the patients, optimal personalized therapy can now be defined.

This Special Issue aims to highlight every aspect of these new coagulation factor concentrates, their efficacy, their safety, and their impact on patients' lives. Original articles, brief reports, communications, research articles, and reviews are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com